Home › Marginal Zone Lymphoma › Maryland
Pag-aaral pangklinika para sa Marginal Zone Lymphoma sa Maryland
6 pag-aaral para sa Marginal Zone Lymphoma ang naghahanap ng mga kalahok sa mga site sa Maryland.
Opisyal na teksto ng pag-aaral (English)
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- American Oncology Partners of Maryland Pa, Bethesda
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT05006716Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
- National Institutes of Health Clinical Center, Bethesda
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 110 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT00923507A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- National Institute of Health, Bethesda
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 2, 2026 · NCT05131022A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- National Institutes of Health Clinical Center, Bethesda
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 20, 2026 · NCT04830137AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- University of Maryland Medical Center - Greenebaum Comprehensive Cancer Center, Baltimore
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Dis 10, 2025 · NCT05602363SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Baltimore
- Massive Bio SYNERGY-AI site, Bethesda
- Massive Bio SYNERGY-AI site, Silver Spring
- at 1 pa
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.